Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MXCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMXCTMaxCyte$1.05-1.4%$0.83$0.64▼$2.40$111.94M1.371.05 million shs397,009 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMXCTMaxCyte-0.93%-2.75%+21.81%+43.36%-51.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMXCTMaxCyte$1.05-1.4%$0.83$0.64▼$2.40$111.94M1.371.05 million shs397,009 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMXCTMaxCyte-0.93%-2.75%+21.81%+43.36%-51.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMXCTMaxCyte 2.20Hold$5.50426.32% UpsideCurrent Analyst Ratings BreakdownLatest NIOX, MXCT, EKF, and CREO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026MXCTMaxCyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/25/2026MXCTMaxCyte Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $5.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMXCTMaxCyte$32.29M3.47N/AN/A$1.57 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMXCTMaxCyte-$44.63M-$0.37N/AN/AN/A-121.16%-20.03%-17.14%N/ALatest NIOX, MXCT, EKF, and CREO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026MXCTMaxCyte-$0.10-$0.04+$0.06-$0.04$7.28 million$6.22 million3/24/2026Q4 2025MXCTMaxCyte-$0.08-$0.06+$0.02-$0.09$9.16 million$6.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMXCTMaxCyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMXCTMaxCyteN/A12.0411.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMXCTMaxCyte68.81%Insider OwnershipCompanyInsider OwnershipMXCTMaxCyte4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMXCTMaxCyte80107.12 million102.73 millionOptionableNIOX, MXCT, EKF, and CREO HeadlinesRecent News About These CompaniesMaxCyte, Inc. (NASDAQ:MXCT) Receives $5.50 Average PT from BrokeragesMay 19 at 3:52 AM | americanbankingnews.comMaxCyte (NASDAQ:MXCT) Raised to Hold at Wall Street ZenMay 16, 2026 | americanbankingnews.comHere’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for InvestorsMay 13, 2026 | insidermonkey.comMaxCyte, Inc. (MXCT) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comMaxCyte Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comMaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2026 | zacks.comMaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 GuidanceMay 12, 2026 | globenewswire.comMaxCyte (MXCT) Expected to Announce Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comMaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026April 29, 2026 | globenewswire.comMaxCyte (MXCT) price target decreased by 11.67% to 4.33April 10, 2026 | msn.comMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 31, 2026 | globenewswire.comMaxCyte (MXCT) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | finance.yahoo.comMaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlookMarch 25, 2026 | seekingalpha.comMaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call TranscriptMarch 25, 2026 | insidermonkey.comMaxCyte, Inc. (MXCT) Q4 2025 Earnings Call TranscriptMarch 25, 2026 | seekingalpha.comMaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ...March 25, 2026 | uk.finance.yahoo.comMaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue EstimatesMarch 24, 2026 | zacks.comMaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 GuidanceMarch 24, 2026 | globenewswire.comMaxCyte Appoints Parmeet Ahuja as Chief Financial OfficerMarch 23, 2026 | globenewswire.comMaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discoveryFebruary 24, 2026 | globenewswire.comMaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026February 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNIOX, MXCT, EKF, and CREO Company DescriptionsMaxCyte NASDAQ:MXCT$1.04 -0.02 (-1.42%) As of 12:54 PM Eastern This is a fair market value price provided by Massive. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Lowe's Finds Support at $215 After Q1 Earnings Sell-Off Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
